Day One Biopharmaceuticals, Inc. () News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1289440,
    "name": "Day One Biopharmaceuticals, Inc.",
    "stock_name": "Day One Biopharmaceuticals, Inc.",
    "full_name": "Day One Biopharmaceuticals, Inc.",
    "name_url": "stocks-analysis/day-one-biopharmaceuticals-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "8.34",
    "chg": -0.09,
    "chgp": "-1.07%",
    "dir": -1,
    "prev_price": "8.43",
    "mcapval": "765.17",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2305,
    "indexname": "S&P 500",
    "isin": "US23954D1090",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "4.14 M",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/day-one-biopharmaceuticals-inc-1289440-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Day One Biopharmaceuticals Experiences Revision in Stock Evaluation Amid Market Challenges",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/day-one-biopharmaceuticals-technical-trend-shifts-from-mildly-bearish-to-sideways-amid-stock-volatility-3640520",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/DayOneBiopharma_technicaldot_3640520.png",
        "date": "2025-10-20 15:33:21",
        "description": "Day One Biopharmaceuticals, Inc. has experienced significant challenges over the past year, with a notable decline in stock value. The company's recent trading reflects volatility, with a 52-week high of $16.76 and a low of $5.63, amid mixed technical indicators and broader market performance."
      },
      {
        "title": "Day One Biopharmaceuticals Hits Day Low of $7.27 Amid Price Pressure",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/day-one-biopharmaceuticals-hits-day-low-of-727-amid-price-pressure-3601771",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/DayOneBiopharma_priceRelatedfactors_3601771.png",
        "date": "2025-10-07 22:31:03",
        "description": "Day One Biopharmaceuticals, Inc. faced notable challenges on October 6, 2025, with a significant stock decline. Despite a substantial increase in net sales last quarter, the company has struggled with long-term growth and negative operating cash flow, raising concerns about its financial health and market position."
      },
      {
        "title": "Day One Biopharmaceuticals Experiences Evaluation Revision Amidst Market Challenges and Mixed Performance Indicators",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/day-one-biopharmaceuticals-technical-trend-shifts-from-bearish-to-mildly-bearish-amid-mixed-signals-3586537",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/DayOneBiopharma_technicaldot_3586537.png",
        "date": "2025-09-30 16:23:23",
        "description": "Day One Biopharmaceuticals, Inc. has recently revised its evaluation amid ongoing market challenges, with its stock priced at $6.77. Over the past year, the company has experienced a significant decline, contrasting sharply with the S&P 500's performance. Technical indicators show mixed signals, reflecting varied momentum and potential volatility."
      },
      {
        "title": "Is Day One Biopharmaceuticals, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-day-one-biopharmaceuticals-inc-technically-bullish-or-bearish-3582553",
        "imagepath": "",
        "date": "2025-09-30 11:19:23",
        "description": "As of 26 September 2025, the technical trend for Day One Biopharmaceuticals, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by a combination of indicators. The MACD shows a mildly bullish signal on the weekly chart but is bearish on the monthly, while the RSI indicates a bullish signal on the monthly but no signal on the weekly. Moving averages are bearish on the daily timeframe, and the KST and OBV are both mildly bearish on the weekly. \n\nIn terms of performance, the stock has underperformed significantly compared to the S&P 500, with a year-to-date return of -46.57% versus the benchmark's 12.96%, and a one-year return of -52.62% compared to 15.64% for the S&P 500...."
      },
      {
        "title": "Is Day One Biopharmaceuticals, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-day-one-biopharmaceuticals-inc-technically-bullish-or-bearish-3578393",
        "imagepath": "",
        "date": "2025-09-29 11:20:13",
        "description": "As of 26 September 2025, the technical trend for Day One Biopharmaceuticals, Inc. has changed from bearish to mildly bearish. The weekly MACD is mildly bullish, while the monthly MACD remains bearish. The RSI shows no signal on the weekly chart but is bullish on the monthly. Bollinger Bands indicate a sideways trend weekly and bearish monthly. Daily moving averages are bearish, and the KST is mildly bullish weekly but bearish monthly. Dow Theory reflects a mildly bearish stance weekly with no trend monthly, and the OBV is mildly bearish weekly with no trend monthly. Overall, the indicators suggest a mildly bearish stance, with the stock underperforming against the S&P 500, although specific return data is not available for comparison...."
      },
      {
        "title": "Is Day One Biopharmaceuticals, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-day-one-biopharmaceuticals-inc-technically-bullish-or-bearish-3576825",
        "imagepath": "",
        "date": "2025-09-28 11:13:17",
        "description": "As of 26 September 2025, the technical trend for Day One Biopharmaceuticals, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by a combination of indicators. The MACD is mildly bullish on a weekly basis but bearish monthly, while the RSI shows a bullish signal monthly but no signal weekly. Moving averages are bearish on a daily basis, and the KST is mildly bullish weekly but bearish monthly. The OBV is mildly bearish weekly, indicating some selling pressure.\n\nIn terms of performance, the stock has significantly underperformed against the S&P 500 across multiple periods, with a year-to-date return of -46.57% compared to the S&P 500's 12.96%, and a one-year return of -52.62% versus 15.64% for the index...."
      },
      {
        "title": "Is Day One Biopharmaceuticals, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-day-one-biopharmaceuticals-inc-technically-bullish-or-bearish-3548232",
        "imagepath": "",
        "date": "2025-09-20 20:12:53",
        "description": "As of 12 August 2025, the technical trend for Day One Biopharmaceuticals, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by the daily moving averages indicating a bearish trend, while the weekly MACD and KST show mild bullishness. The monthly indicators, including MACD and Bollinger Bands, are bearish. The RSI shows a bullish signal on the monthly timeframe but no signal on the weekly. \n\nIn terms of performance, the stock has underperformed the S&P 500 across multiple periods, with a year-to-date return of -43.09% compared to the S&P 500's 12.22%, and a one-year return of -47.72% versus 17.14%...."
      },
      {
        "title": "Is Day One Biopharmaceuticals, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-day-one-biopharmaceuticals-inc-overvalued-or-undervalued-3544331",
        "imagepath": "",
        "date": "2025-09-20 18:43:34",
        "description": "As of 30 July 2024, the valuation grade for Day One Biopharmaceuticals, Inc. has moved from does not qualify to risky, indicating increased concerns regarding its financial health. The company appears to be overvalued given its significant negative metrics, including a Price to Book Value of 1.52, an EV to Sales ratio of 1.58, and an alarming ROCE of -2922.95%. In comparison, SAGE Therapeutics, Inc., a peer in the same industry, has a more favorable EV to EBITDA of -0.5626, highlighting the challenges faced by Day One.\n\nThe stock has underperformed against the S&P 500 across multiple time frames, with a year-to-date return of -43.09% compared to the S&P 500's 12.22%. This stark contrast reinforces the notion that Day One Biopharmaceuticals is currently overvalued in the market...."
      }
    ],
    "total": 12,
    "sid": "1289440",
    "stock_news_url": "https://www.marketsmojo.com/news/day-one-biopharmaceuticals-inc-1289440"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Day One Biopharmaceuticals Experiences Revision in Stock Evaluation Amid Market Challenges

2025-10-20 15:33:21

Day One Biopharmaceuticals, Inc. has experienced significant challenges over the past year, with a notable decline in stock value. The company's recent trading reflects volatility, with a 52-week high of $16.76 and a low of $5.63, amid mixed technical indicators and broader market performance.

Day One Biopharmaceuticals Hits Day Low of $7.27 Amid Price Pressure

2025-10-07 22:31:03

Day One Biopharmaceuticals, Inc. faced notable challenges on October 6, 2025, with a significant stock decline. Despite a substantial increase in net sales last quarter, the company has struggled with long-term growth and negative operating cash flow, raising concerns about its financial health and market position.

Day One Biopharmaceuticals Experiences Evaluation Revision Amidst Market Challenges and Mixed Performance Indicators

2025-09-30 16:23:23

Day One Biopharmaceuticals, Inc. has recently revised its evaluation amid ongoing market challenges, with its stock priced at $6.77. Over the past year, the company has experienced a significant decline, contrasting sharply with the S&P 500's performance. Technical indicators show mixed signals, reflecting varied momentum and potential volatility.

Is Day One Biopharmaceuticals, Inc. technically bullish or bearish?

2025-09-30 11:19:23

As of 26 September 2025, the technical trend for Day One Biopharmaceuticals, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by a combination of indicators. The MACD shows a mildly bullish signal on the weekly chart but is bearish on the monthly, while the RSI indicates a bullish signal on the monthly but no signal on the weekly. Moving averages are bearish on the daily timeframe, and the KST and OBV are both mildly bearish on the weekly. In terms of performance, the stock has underperformed significantly compared to the S&P 500, with a year-to-date return of -46.57% versus the benchmark's 12.96%, and a one-year return of -52.62% compared to 15.64% for the S&P 500....

Is Day One Biopharmaceuticals, Inc. technically bullish or bearish?

2025-09-29 11:20:13

As of 26 September 2025, the technical trend for Day One Biopharmaceuticals, Inc. has changed from bearish to mildly bearish. The weekly MACD is mildly bullish, while the monthly MACD remains bearish. The RSI shows no signal on the weekly chart but is bullish on the monthly. Bollinger Bands indicate a sideways trend weekly and bearish monthly. Daily moving averages are bearish, and the KST is mildly bullish weekly but bearish monthly. Dow Theory reflects a mildly bearish stance weekly with no trend monthly, and the OBV is mildly bearish weekly with no trend monthly. Overall, the indicators suggest a mildly bearish stance, with the stock underperforming against the S&P 500, although specific return data is not available for comparison....

Is Day One Biopharmaceuticals, Inc. technically bullish or bearish?

2025-09-28 11:13:17

As of 26 September 2025, the technical trend for Day One Biopharmaceuticals, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by a combination of indicators. The MACD is mildly bullish on a weekly basis but bearish monthly, while the RSI shows a bullish signal monthly but no signal weekly. Moving averages are bearish on a daily basis, and the KST is mildly bullish weekly but bearish monthly. The OBV is mildly bearish weekly, indicating some selling pressure. In terms of performance, the stock has significantly underperformed against the S&P 500 across multiple periods, with a year-to-date return of -46.57% compared to the S&P 500's 12.96%, and a one-year return of -52.62% versus 15.64% for the index....

Is Day One Biopharmaceuticals, Inc. technically bullish or bearish?

2025-09-20 20:12:53

As of 12 August 2025, the technical trend for Day One Biopharmaceuticals, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by the daily moving averages indicating a bearish trend, while the weekly MACD and KST show mild bullishness. The monthly indicators, including MACD and Bollinger Bands, are bearish. The RSI shows a bullish signal on the monthly timeframe but no signal on the weekly. In terms of performance, the stock has underperformed the S&P 500 across multiple periods, with a year-to-date return of -43.09% compared to the S&P 500's 12.22%, and a one-year return of -47.72% versus 17.14%....

Is Day One Biopharmaceuticals, Inc. overvalued or undervalued?

2025-09-20 18:43:34

As of 30 July 2024, the valuation grade for Day One Biopharmaceuticals, Inc. has moved from does not qualify to risky, indicating increased concerns regarding its financial health. The company appears to be overvalued given its significant negative metrics, including a Price to Book Value of 1.52, an EV to Sales ratio of 1.58, and an alarming ROCE of -2922.95%. In comparison, SAGE Therapeutics, Inc., a peer in the same industry, has a more favorable EV to EBITDA of -0.5626, highlighting the challenges faced by Day One. The stock has underperformed against the S&P 500 across multiple time frames, with a year-to-date return of -43.09% compared to the S&P 500's 12.22%. This stark contrast reinforces the notion that Day One Biopharmaceuticals is currently overvalued in the market....

View All News